Background {#Sec1}
==========

Secondary hyperparathyroidism (SHPT) is associated with adverse outcomes in patients receiving maintenance dialysis \[[@CR1], [@CR2]\]. Anecdotally, physicians appear to have widely variable criteria regarding which patients they choose to refer for parathyroidectomy, at least in the US. Perhaps reflecting uncertainty over its role, rates of parathyroidectomy have changed substantially over time in recent decades \[[@CR3]\]. While guidelines recommend parathyroidectomy in patients with severe SHPT \[[@CR4]\], how it might be used most optimally is uncertain. Parathyroidectomy has been shown to be associated with improved outcomes in some studies \[[@CR5], [@CR6]\]; however, it has also been shown to be associated with mortality, protracted hypocalcemia, and over-suppression of parathyroid hormone (PTH) \[[@CR7]\], and its results with regard to mineral metabolic control are often suboptimal \[[@CR8]\]. Thus, understanding the differences between hemodialysis patients who do and do not undergo parathyroidectomy may be important. However, the effect of geographic variation, which is associated with a variety of outcomes and care differences in the dialysis population \[[@CR9], [@CR10]\] has not been examined in the context of parathyroidectomy. We therefore conducted a retrospective cohort study to examine whether parathyroidectomy use varies geographically in the United States.

Methods {#Sec2}
=======

Using the United States Renal Data System end-stage renal disease database, we identified patients aged 18 years or older who were receiving in-center hemodialysis between 2007 and 2009, were covered by Medicare Part A (inpatient, outpatient, skilled nursing facility, hospice, or home health agency) and Part B (physician/supplier) as primary payer, and had been receiving hemodialysis for at least 1 year. Parathyroidectomy was identified from inpatient claims using International Classification of Diseases, Ninth Revision, Clinical Modification procedure codes 06.81 (complete parathyroidectomy), 06.89 (partial parathyroidectomy and parathyroidectomy not otherwise specified), and 06.95 (parathyroid tissue reimplantation).

Patient characteristics, derived from the end-stage renal disease database Medical Evidence Report and Medicare claims, were assessed on the parathyroidectomy date and on January 1 for non-parathyroidectomy patients. Characteristics included age, sex, race, body mass index, cause of renal disease, dialysis duration, and common comorbid conditions, as have been used previously \[[@CR11]\]. Our proxy for geography was US End-Stage Renal Disease Network (*n* = 18, Table [1](#Tab1){ref-type="table"}), geographically based regions designed to facilitate care and monitor quality on a regional level. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for parathyroidectomy were estimated from a logistic model adjusting for the factors described above. The adjusted ORs for the renal networks were calculated using the whole nation as the reference. All statistical analyses were conducted using SAS software, Version 9.2, SAS Institute Inc., Cary, NC, USA.Table 1End-stage renal disease networks and associate US statesNetwork numberStates and territories1Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont2New York3New Jersey, Puerto Rico, Virgin Islands4Delaware, Pennsylvania5District of Columbia, Maryland, Virginia, West Virginia6Georgia, North Carolina, South Carolina7Florida8Alabama, Mississippi, Tennessee9Indiana, Kentucky, Ohio10Illinois11Michigan, Minnesota, North Dakota, South Dakota, Wisconsin12Iowa, Kansas, Missouri, Nebraska13Arkansas, Louisiana, Oklahoma14Texas15Arizona, Colorado, Nevada, New Mexico, Utah, Wyoming16Alaska, Idaho, Montana, Oregon, Washington17American Samoa, Guam, Mariana Islands, Hawaii, Northern California18Southern California

Results {#Sec3}
=======

We identified 286,569 patients who satisfied our inclusion criteria, of whom 4435 (1.5%) underwent parathyroidectomy (Table [2](#Tab2){ref-type="table"}). Parathyroidectomy frequency was 2.3 fold greater, in unadjusted terms, for the least-frequently performing region (0.97% of patients, Network 18) compared with the most-frequently performing region (2.20% of patients, Network 6).Table 2Characteristics of patients who did and did not undergo parathyroidectomyPTXNon-PTX*n*%*n*%Total4435100282,134100Age at PTX, years 19--44176439.838,83013.8 45--64215448.6110,78839.3 65--744109.269,55024.7 ≥ 751072.462,96622.3Race White168538.0156,63855.5 Black255157.5108,24638.4 Other1994.517,2506.1Sex Male229851.8155,25755.0 Female213748.2126,87745.0ESRD primary cause Diabetes101322.8128,20245.4 Hypertension146233.081,23128.8 Glomerulonephritis93421.127,2509.7 Other/unknown/missing102623.145,45116.1BMI, kg/m^2^ \< 181513.480742.9 18-- \< 25121727.488,83831.5 25-- \< 30102623.178,93828.0 30-- \< 3577217.449,31017.5 35-- \< 4051711.725,9879.2 ≥ 4053612.123,3838.3 Missing2164.976042.7Dialysis duration, years 1-- \< 353812.1151,77853.8 3-- \< 597021.958,34120.7 \> 5292766.072,01525.5Comorbidities Diabetes195444.1185,02965.6 ASHD154234.8131,67846.7 CHF197344.5144,79251.3 CVA/TIA52211.857,53220.4 PVD138931.3112,97240.0 Dysrhythmia105723.877,32027.4 Other cardiac disease162336.691,95532.6Network 11513.494073.3 21924.316,8086.0 31563.511,8874.2 41182.711,6894.1 52605.917,0806.1 666715.029,66310.5 72535.716,0765.7 83648.217,0606.1 92936.621,1527.5 101543.511,9774.3 112525.718,8146.7 121994.511,1884.0 132545.712,0734.3 1448711.027,8929.9 151824.112,0164.3 161393.172542.6 171363.111,8604.2 181784.018,2386.5*ASHD* atherosclerotic heart disease, *BMI* body mass index, *CHF* congestive heart failure, *CVA/TIA* cerebrovascular accident/transient ischemic attack, *ESRD* end-stage renal disease, *PTX* parathyroidectomy, *PVD* peripheral vascular disease

Network was associated with substantial variability in likelihood of parathyroidectomy (Fig. [1](#Fig1){ref-type="fig"}). Even after adjustment for all characteristics in Table [2](#Tab2){ref-type="table"}, adjusted ORs for parathyroidectomy varied from 0.67 (95% CIs 0.58--0.78) to 1.37 (1.17--1.60) between the least- and most-frequently performing regions. Adjusted ORs were more than 20% higher than the national level in four networks and more than 20% lower in four networks.Fig. 1Odds ratios for factors associated with parathyroidectomy. ASHD, atherosclerotic heart disease; CHF, congestive heart failure; CVA, cerebrovascular accident; ESRD, end-stage renal disease; PVD, peripheral vascular disease

In addition, younger age (adjusted OR 1.95, 95% CI 1.83--2.08, vs. age 45--64 years), female sex (1.23, 1.16--1.30), black race (1.29, 1.21--1.37 vs. white), dialysis duration \> 5 years (3.70, 3.27--4.05 vs. 1- \< 3 years), and atherosclerotic heart disease (1.15, 1.07--1.23) were associated with parathyroidectomy (*P* \< 0.001). Diabetes (0.82, 0.76--0.89) and history of stroke (0.82, 0.74--0.89) were inversely associated with parathyroidectomy.

Results for the multivariable model for factors associated with parathyroidectomy are shown in Table [3](#Tab3){ref-type="table"}.Table 3Multivariable model for factors associated with parathyroidectomyFactorsHR (95% CI)*P*Age at PTX, years 19--441.95 (1.83--2.08)\<0.001 45--641 (Referent) 65--740.37 (0.34--0.42)\< 0.001 ≥ 750.11 (0.09--0.13)\< 0.001Race White1 (Referent) Black1.29 (1.21--1.37)\< 0.001 Other0.89 (0.77--1.03)0.11Sex Male0.82 (0.77--0.87)\< 0.001 Female1 (Referent)ESRD primary cause Diabetes0.58 (0.53--0.64)\< 0.001 Hypertension1 (Referent) Glomerulonephritis1.11 (1.02--1.21)0.011 Other/unknown/missing1.04 (0.96--1.13)0.30BMI, kg/m^2^ \< 180.96 (0.82--1.13)0.62 18-- \< 251 (Referent) 25-- \< 301.10 (1.02--1.20)0.016 30-- \< 351.32 (1.21--1.44)\< 0.001 35-- \< 401.48 (1.34--1.64)\< 0.001 ≥ 401.53 (1.38--1.69)\< 0.001 Missing1.08 (0.94--1.24)0.29Dialysis duration, years 1-- \< 31 (Referent) 3-- \< 52.23 (2.02--2.47)\< 0.001 ≥ 53.70 (3.37--4.05)\< 0.001Comorbid conditions Diabetes0.82 (0.76--0.89)\< 0.001 ASHD1.15 (1.07--1.23)\< 0.001 CHF1.08 (1.01--1.15)0.019 CVA/TIA0.82 (0.74--0.89)\< 0.001 PVD0.97 (0.91--1.04)0.42 Dysrhythmia1.08 (1.00--1.16)0.058 Other cardiac disease1.37 (1.29--1.47)\< 0.001ESRD Network 161.37 (1.17--1.60)\< 0.001 11.35 (1.17--1.57)\< 0.001 121.24 (1.09--1.40)0.001 131.24 (1.08--1.37)0.001 61.18 (1.09--1.28)\< 0.001 81.17 (1.06--1.29)0.002 151.14 (0.99--1.31)0.067 141.13 (1.03--1.23)0.008 111.03 (0.92--1.16)0.60 71.01 (0.90--1.13)0.91 30.97 (0.84--1.12)0.69 90.92 (0.83--1.02)0.12 50.88 (0.79--0.99)0.032 100.88 (0.76--1.01)0.070 170.80 (0.68--0.93)0.005 20.78 (0.68--0.88)\< 0.001 40.69 (0.59--0.82)\< 0.001 180.67 (0.58--0.78)\< 0.001Year 20071 (Referent) 20080.89 (0.83--0.95)0.001 20090.83 (0.78--0.89)\< 0.001*ASHD* atherosclerotic heart disease, *BMI* body mass index, *CHF* congestive heart failure, *CI* confidence interval, *CVA/TIA* cerebrovascular accident/transient ischemic attack, *ESRD* end-stage renal disease, *HR* hazard ratio, *PTX* parathyroidectomy, *PVD* peripheral vascular disease

Discussion {#Sec4}
==========

SHPT treatment presents a complex clinical challenge. Practice guidelines provide direction \[[@CR4]\] but suffer from lack of randomized clinical trial data, resulting in uncertainty about the benefits and risks of parathyroidectomy. Understanding use of parathyroidectomy is important, given widely varying recent data demonstrating both clinical benefits \[[@CR5], [@CR6]\], as well as high rates of adverse events and suboptimal mineral metabolic outcomes \[[@CR7], [@CR8]\]. Our large retrospective analysis demonstrated substantial geographic variation in parathyroidectomy use. This difference was not driven solely by outliers at the extremes; AORs were 20% higher or lower than unity in eight Networks. This could reflect regional differences in many potential factors, including provider-related ones such as particular treatment approaches instilled during training, access to qualified parathyroid surgeons, or local "cultures" of treatment, all of which might play substantial roles in how care is differentially rendered \[[@CR12]\].

Certain demographic factors, specifically younger age and black race, were also associated with likelihood of parathyroidectomy; this was not unexpected given that both of these factors have been previously reported to be associated with more severe SHPT \[[@CR2], [@CR13]\]. Dialysis duration was also associated with parathyroidectomy, possibly because the changes that characterize severe parathyroid gland dysregulation may take many years to develop \[[@CR14]\]; alternatively, providers may be resorting to parathyroidectomy only after prolonged attempts at other interventions prove fruitless. The inverse associations between older age and history of stroke and parathyroidectomy may reflect poor surgical candidacy in the provider's estimation.

Our study was limited by lack of patient-level data about degree of PTH control, SHPT therapies employed, or other SHPT markers such as serum calcium and phosphorus, which likely predict the parathyroidectomy decision. For example, use of cinacalcet, which has been shown to reduce rates of parathyroidectomy \[[@CR15]\], might vary widely by region, although we have no *a priori* reason to posit this and it seems unlikely to account for a more than 2-fold variation in parathyroidectomy rates. Additionally, we lack information about geographic variation in renal transplant; fewer individuals in areas in which early transplant occurs more commonly might be at risk of developing severe SHPT and subsequently undergoing parathyroidectomy. Again, given the magnitude of variation between the most- and least-frequently parathyroidectomy performing regions, case mix alone is unlikely to fully account for it.

Conclusion {#Sec5}
==========

Even after adjustment of a variety of case-mix variables, use of parathyroidectomy varies substantially by geography in the US; the factors responsible should be further investigated. Given recent information about the potential risks associated with parathyroidectomy \[[@CR7], [@CR8]\], the factors responsible for shaping the decision to undertake it should also be the subject of future investigation.
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